MARKET

DMAC

DMAC

Diamedica Therapeutics Inc
NASDAQ
6.32
-0.21
-3.22%
After Hours: 6.50 +0.18 +2.85% 18:09 05/08 EDT
OPEN
6.50
PREV CLOSE
6.53
HIGH
6.61
LOW
6.19
VOLUME
276.94K
TURNOVER
--
52 WEEK HIGH
10.42
52 WEEK LOW
3.475
MARKET CAP
340.54M
P/E (TTM)
-8.9480
1D
5D
1M
3M
1Y
5Y
1D
H.C. Wainwright Keeps Their Buy Rating on Diamedica Therapeutics (DMAC)
TipRanks · 2d ago
DiaMedica outlines ReMEDy2 interim analysis by end of 2026 with potential 300-700 patient resample size
Seeking Alpha · 2d ago
DiaMedica Therapeutics reports Q1 EPS (19c), consensus (19c)
TipRanks · 3d ago
DiaMedica sees cash, equivalents funding operations through 2027
TipRanks · 3d ago
DiaMedica Therapeutics GAAP EPS of -$0.19 misses by $0.01
Seeking Alpha · 3d ago
DiaMedica Q1 net, operating income miss estimates; R&D costs to rise moderately
Reuters · 3d ago
DiaMedica Q1 FY26 net loss widens to $10 million
PUBT · 3d ago
DIAMEDICA THERAPEUTICS INC - REPORTS $51.3 MLN IN CASH AND INVESTMENTS, RUNWAY THROUGH 2027
Reuters · 3d ago
More
About DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.

Webull offers DiaMedica Therapeutics Inc stock information, including NASDAQ: DMAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DMAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DMAC stock methods without spending real money on the virtual paper trading platform.